Migration Letters

Volume: 19, No: S8 (2022), pp. 396-405 ISSN: 1741-8984 (Print) ISSN: 1741-8992 (Online) www.migrationletters.com

Factors Associated with Poor Glycemic Control among Patients with Type 2 Diabetes Miletus

Tariq Saleh Alosaimi¹, Ali Mohammed Assiri², Abdullah Mesfer Ali Alghamdi³, Majed Salem Saleh Althobaiti⁴, Abdullah Abdulrahman Mohammed Alsofyani⁵, Saleh Motair Soqair Altalhi⁶, Suliman Mohammed Saed Alghamdi⁷, Fares saed salah Alzahrani⁸, Sami Mohammed Saed Alghamdi⁹, Maram Abdulrahim Misfer Alghamdi¹⁰, Talal Awad Melfi ALOTAIBi¹¹

Abstract

Objectives: Determine factors associated with poor glycemic control among patients with Type 2 diabetes in Al-Thawra Hospital in Sana'a city. Methods: A systematic random sample of 611 patients was selected from all patients with Type 2 diabetes over a period of 6 months in 2022 (April to October 2022). A restructured questionnaire sought information about sociodemographic, clinical characteristics, self-care management behaviors, medication adherence, barriers to adherence, and attitudes toward diabetes. Weight, height, and waist circumferences were measured. All available last readings of hemoglobin A1c (HbA1c), fasting blood sugar measurements, and lipids were abstracted from patients' records. Poor glycemic control was defined as HbA1c \geq 6.5%. Results: Of the total 611 patients, 66.6% had HbA1c \geq 6.5%. In the multivariate analysis, increased duration of diabetes (N7 years vs. \leq 7years) (OR=1.99, P \leq .0005), not following eating plan as recommended by dietitians (OR=2.98, $P\leq .0005$), negative attitude towards diabetes (OR=1.04, P=.020, and increased barriers to adherence scale scores were significantly)associated with increased odds of poor glycemic control (OR=1.02, P=.002). Conclusion: The proportion of patients with poor glycemic control was high, which was comparable to that reported from many previous studies. Longer duration of diabetes and not adherent to diabetes self-care management behaviors were associated with poor glycemic control. Recommendation: An educational program that emphasizes lifestyle modification with the importance of adherence to treatment regimen would be of great benefit in glycemic control.

Key words: Diabetes; Glycemic control.

¹ Nursing and Midwifery, Erada & Mental Health complex in Taif, Saudi Arabia.

² Nursing and Midwifery, Erada & Mental Health complex in Taif, Saudi Arabia.

³ Nursing and Midwifery, Erada & Mental Health complex in Taif, Saudi Arabia.

⁴ Nursing and Midwifery, Erada & Mental Health complex in Taif, Saudi Arabia.

⁵ Nursing and Midwifery, Erada & Mental Health complex in Taif, Saudi Arabia.

⁶ Nursing and Midwifery, Erada & Mental Health complex in Taif, Saudi Arabia.

⁷ Nursing, Erada complex for mental health AlBaha, Saudi Arabia.

⁸ Nursing Technician, Security forces specialized comperhensive Clinics Albaha, Saudi Arabia.

⁹ Nursing, Erada complex for mental health AlBaha, Saudi Arabia.

¹⁰ Specialist Nurse, Erada complex for mental health-AlBaha, Saudi Arabia.

¹¹ Specialist Nursing, Albjadyah general hospital, Saudi Arabia.

Introduction

Diabetes is a chronic illness that requires continuing medical care and education to prevent acute complications and to reduce the risk of long-term complication.1 Poor glycemic control is the most common cause of hospital admissions in diabetics 2. More than 135 million people worldwide had diabetes mellitus (DM) in 1995, which are approximately 4% of the global population. Approximately 300 million people are expected to have the disease by 2025 (5.4%). (Habib, S. S., & Aslam, M., 2003).

Diabetes mellitus is a major cause of morbidity and mortality. In a recent study in Sana'a, the age-standardized prevalence of diabetes mellitus (DM) and impaired fasting glucose were 17.1% and 7.8%, respectively (Ajlouni, Khader, Batieha, Ajlouni, & EL-khateeb, 2008). In the Arab region, the overall prevalence of DM in the Kingdom of Saudi Arabia is 23.7% among people with age between 30 and 70 years (Al-Nozha et al., 2004). The highest comparative diabetes prevalence rates in 2021 are reported in Pakistan (30.8%), French Polynesia (25.2%) and Kuwait (24.9%) (Table 3.5). These countries are also expected to have the highest overall comparative diabetes prevalence in 2045, with figures in Pakistan reaching 33.6%, Kuwait 29.8% and French Polynesia 28.2%. (International Diabetes Federation, 2021).

Several large clinical trials have demonstrated that tight blood glucose control correlates with a reduction in the microvascular complications of diabetes (The Diabetes Control and Complications Trial Research Group, 1993; UK Prospective Diabetes Study (UKPDS) Group, 1998). The American Diabetes Association (ADA) has designated HbA1c level of 6.5% as a goal of optimal blood glucose control (American Diabetes Association, 2013), and the American Association of Clinical Endocrinologists has further recommended HbA1c level of b6.5% (The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus, 2012). Despite the evidence from large randomized controlled trials establishing the benefit of intensive diabetes management in reducing microvascular and macrovascular complications (Saadine et al., 2002; Stratton et al., 2000; UK Prospective Diabetes Study (UKPDS) Group, 1998), a high proportion of patients remain poorly controlled (Karter et al., 2005). Poor and inadequate glycemic control among patients with Type 2 diabetes constitutes a major public health problem and a major risk factor for the development of diabetes complications. Glycemic control remains the major therapeutic objective for the prevention of target organ damage and other complications arising from diabetes (Koro, Bowlin, Bourgeois, & Fedder, 2004).

In clinical practice, optimal glycemic control is difficult to obtain on a long-term basis because the reasons for poor glycemic control in Type 2 diabetes are complex (Wallace & Matthews, 2000). Both patient- and healthcare- provider-related factors may contribute to poor glycemic control(Rhee et al., 2005; Wallace & Matthews, 2020). Risk factors of Diabetes mellitus type-2 are family history of diabetes mellitus, previous gestational diabetes mellitus history, old age, obesity, type of diet and lack of physical exercise (Muhammad Farman and Khansa Ghaffar,2019). Prevention and treatment involve a healthy diet, and physical exercise (Shouip Hossam A., 2014).

Aim of the study:

This study was conducted to determine factors associated with poor glycemic control among patients with Type 2 diabetes.

design

Cross-sectional study was used to achieve the aim of the study.

Study setting

This study is a cross sectional study that was conducted.

Determine factors associated with poor glycemic control among patients with Type 2

diabetes in Makkah hospital.

Pilot study

A pilot study was carried out on (30) (5%) patients in Makkah Hospital before the period of data collection. It was done to test the clarity and practicability of the tools. The results of the data obtained from the pilot study should help in the modification of the tools, items have been modified and corrected as needed.

Participants

A Convenience sample was used to include 611 patients according to the following inclusion criteria: gender, age, employee, level of education, Body Max Index (BMI), duration of diabetics, Type of treatment.

The data was collected from January 2022 to May 2022.

The length of data collection period to ensure the representativeness. Participants were informed about the objective of the study. Based on their approval, participants were asked to read carefully and sign a consent form. Patients with Type 1 DM were excluded from the study.

Data collection

This study was approved by the ethical committee. Personal interview was held to collect data including age, gender, level of education, occupation (employed, not employed), and duration of diabetes. Self-care management behaviors were collected to assess adherence to diabetes regimens that included diet, physical exercise, and blood glucose testing. Medication adherence was measured using a validated index proposed by Choo, Rand, Inui, Lee, and Platt (1999). Barriers to adherence were assessed by a scale that was developed by Glasgow, Maccaul, and Schafer (1986). Respondents were asked to rate how frequently they experience various barriers to self-care activity using a seven-point scale that ranges from 1 (very rarely) to 7 (daily). The scale was scored by averaging the responses across the items. Higher scores indicate a higher frequency of barriers to regimen behavior.

Attitude towards diabetes was assessed using the attitude towards diabetes scale, which was developed by Fitzgerald et al. (1996). The scale consists of 10 items. The first six items have been negatively worded, which required reverse scoring. Each item was rated on a five- point Likert scale (1=strongly disagree, 2=disagree, 3=neutral, 4=agree, and 5=strongly agree). The total score ranged from a minimum score of 10 to a maximum score of 50. A higher score on the scale indicates a negative attitude towards diabetes and that the patient would have possible problems adapting with diabetes daily.

Family and friend support for diabetes and its management was measured by the family and friend support scale, which was developed by Fitzgerald et al. (1996). The scale consists of 11 items. Two items have been negatively worded which required reverse scoring. Each item was rated on a five-point Likert scale from 1 representing the least supportive response to 5 representing the most supportive response. The total scores range from a minimum score of 11 to a maximum score of 55. Generally, the higher scores on the scale indicate more family and friend support for diabetes and its management.

Weight, height, and waist circumferences were measured while the subject wearing light clothes and taking the shoes off. Weight was taken to the nearest 0.5 kg, and height was taken to the nearest 0.5 cm. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Blood pressure was measured using standardized mercury sphygmomanometers. A trainee nurse performed the procedure while the patient was in a sitting position with the arm at the level of the heart and after 10 minutes of rest.

All available last readings of HbA1c, fasting blood sugar measurements, and lipid profile [high-density lipoprotein (HDL), low- density lipoprotein (LDL), triglyceride, and

cholesterol] were abstracted from patients' records. The lipid profile was analyzed using the automated spectrophotometer, and HbA1c was analyzed using high-performance liquid chromatography.

Operational definition

The diagnosis of DM was reached according to the ADA criteria (American Diabetes Association, 2013). Duration of diabetes in years since diagnosis of diabetes was categorized as \leq 7 years. People with systolic/diastolic blood pressure levels \geq 130/80 mmHg or who were on antihypertensive medication were defined as having hypertension (American Diabetes Association, 2013). BMI was categorized as normal if BMI was 25 kg/m2, overweight if BMI was 25–29.9 kg/m2, and obese if BMI was \geq 30 kg/m2 (World Health Organization, 1995). Glycemic status was categorized as good glycemic control if HbA1c \geq 6.5% (American Diabetes Association, 2013).

Criteria for abnormal lipid profile levels were based on the ADA criteria (American Diabetes Association, 2020). Hypercholesterolemia refers to a total cholesterol level \geq 200 mg/dl. HDL was considered low when the level was 40 mg/dl in males and 50 mg/dl in females. LDL was considered high when the level was \geq 100 mg/dl. Hypertriglyceridemia refers to a level \geq 150 mg/dl. Dyslipidemia was defined as the presence of one or more of the previous abnormalities in serum lipids. Patients receiving medications for any of the above conditions were classified as having the condition.

Following an eating plan as recommended by the dietitian indicated that patients were following the eating plan for 3 days or more in the previous 7 days. Patients were engaged, at least 30 min, in physical exercise if they walked 3 days or more in the previous 7 days. Self-monitoring blood glucose was defined if patients performed home glucose monitoring for 5 days or more in the previous 7 days. Patients were classified as highly adherent if they never missed their medications in the previous 7 days.

Limitation of the study

This study was the first study conducted in Sana'a to determine the factors associated with poor glycemic control. However, this study is cross-sectional, where a causal relationship between the independent and dependent variables cannot be established, so a longitudinal study is needed to assess the relationship between those variables over time.

Statistical analysis

Statistical analysis was carried out using Statistical Package for Social Sciences (SPSS, version 21). Data were described using mean (SD) for continuous variables and proportions for categorical variables. The chi-square test was used to assess the statistical significance of the difference in the percentages of poor glycemic control according to independent categorical variables. Binary logistic regression was conducted to determine factors that are associated with poor glycemic control. The P- value of 0.05 was considered statistically significant.

Results

This study included a total of 611patients (302 men and 309 women) with Type 2 DM aged between 24 and 84 years, with a mean (S.D.) of 52.2 (9.1) years. More than half (54.5%) of patients were illiterate. More than two third (75.1%) of the patients were not employed. Their clinical, anthropometric, and relevant characteristics are shown in Table 1. Nearly four-fifths (77.7%) of patients suffer of hypertension, more than half (58.9) of patients are overweight according to BMI, four-fifths (78.9%) of patients complain of dyslipidemia, and less than one-fifth (14.6%) of patients have high cholesterol more than 200 mg/dL.

About 62.4% of patients were on oral antidiabetic agents, 32.0% of patients were on combination of oral antidiabetic agents and insulin and only 5.6% of patients were on insulin alone.

Variable n (%) BMI, mean (S.D.) = 31.8 (5.7) 201 32.9 Normal 201 32.9 Overweight 355 58.1 Obesity 55 9 Hypertension 475 77.7 No 136 22.3 Dyslipidemia 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) 2200 89 14.6 ≥ 200 89 14.6 2200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) 2150 258 42.2 42.2 < 150 258 42.2 46.2 100 329 53.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) 2100 282 46.2 46.2 < 100 282 46.2 46.2 46.2 48.0 < 40 220 145 48.0 48.0			
Normal 201 32.9 Overweight 355 58.1 Obesity 55 9 Hypertension 77.7 No 136 22.3 Dyslipidemia 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) 2200 89 14.6 < 200	Variable	n	(%)
Overweight 355 58.1 Obesity 55 9 Hypertension 475 77.7 No 136 22.3 Dyslipidemia 482 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) 200 89 14.6 ≥ 200 89 14.6 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) 2150 258 42.2 ≤ 150 258 42.2 2150 258 42.2 < 150 258 42.2 46.2 46.2 46.2 400 329 53.8 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) 2100 282 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.2 46.	BMI, mean (S.D.) = 31.8 (5.7)		
Obesity 55 9 Hypertension Yes 475 77.7 No 136 22.3 Dyslipidemia Yes 482 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) >200 89 14.6 < 200	Normal	201	32.9
Hypertension Yes 475 77.7 No 136 22.3 Dyslipidemia 136 22.3 Yes 482 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) 200 89 >200 89 14.6 < 200	Overweight	355	58.1
Yes 475 77.7 No 136 22.3 Dyslipidemia 78.9 Yes 482 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) 200 89 14.6 ≥ 200 89 14.6 < 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) 258 42.2 ≥ 150 258 42.2 < 150 258 42.2 < 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) 282 46.2 < 100 282 46.2 < 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) 10.1 (9.7)	Obesity	55	9
No 136 22.3 Dyslipidemia	Hypertension		
Dyslipidemia Yes 482 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) ≥ 200 89 14.6 ≥ 200 89 14.6 < 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) ≥ 150 258 42.2 < 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) ≥ 100 282 46.2 < 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7)	Yes	475	77.7
Yes 482 78.9 No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) ≥ 200 89 14.6 ≥ 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) ≥ 150 258 42.2 < 150 258 42.2 < 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) ≥ 100 282 46.2 < 100 282 46.2 ≤ 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) $= 102.6 (31.1)$ $= 102.6 (31.1)$	No	136	22.3
No 129 21.1 Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) ≥ 200 89 14.6 ≥ 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) ≥ 150 258 42.2 < 150 258 42.2 < 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) ≥ 100 282 46.2 < 100 282 46.2 ≤ 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) $= 100$ $= 100$ $= 100$	Dyslipidemia		
Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1) ≥ 200 89 14.6 < 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) ≥ 150 258 42.2 < 150 258 42.2 < 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) ≥ 100 282 46.2 < 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7)	Yes	482	78.9
$ \ge 200 \qquad 89 \qquad 14.6 \\ < 200 \qquad 522 \qquad 85.4 \\ \hline Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) \\ \ge 150 \qquad 258 \qquad 42.2 \\ < 150 \qquad 353 \qquad 57.8 \\ \hline Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) \\ \ge 100 \qquad 282 \qquad 46.2 \\ < 100 \qquad 329 \qquad 53.8 \\ \hline High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) \\ \hline $	No	129	21.1
< 200 522 85.4 Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) \geq \geq \geq 150 258 42.2 $<$ 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) \geq \geq \geq 100 282 46.2 $<$ 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) $=$ $=$	Cholesterol (mg/dl), mean (S.D.)=163.4 (36.1)		
Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3) ≥ 150 258 42.2 < 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) \geq \geq ≥ 100 282 46.2 < 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) $=$	≥200	89	14.6
$ \ge 150 \\ \le 150 \\ \le 150 \\ \ge 150 \\ \ge 150 \\ \ge 150 \\ \ge 100 \\ \ge 100 \\ \le 100 \\ \le 100 \\ \le 100 \\ \ge 102.6 (31.1) \\ \ge 100 \\ \ge 102.6 (31.1) \\ \ge 100 \\ \ge 100 \\ \ge 102.6 (31.1) \\ \ge 100 \\ \ge 100 \\ \ge 102.6 (31.1) \\ \ge 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\ = 100 \\$	< 200	522	85.4
< 150 353 57.8 Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) ≥ 100 282 46.2 < 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7) $=$	Triglyceride (mg/dl), mean (S.D.)=152.5 (71.3)		
Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (31.1) ≥ 100 282 < 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7)	≥150	258	42.2
$\geq 100 < 100 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7)$	< 150	353	57.8
< 100 329 53.8 High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7)	Low density lipoprotein (mg/dl), mean (S.D.)=102.6 (3	1.1)	
High density lipoprotein (mg/dl), male: mean (S.D.)=40.1 (9.7)	≥100	282	46.2
	< 100	329	53.8
>40 220 145 48.0	High density lipoprotein (mg/dl), male: mean (S.D.)=40	0.1 (9.7)	
	≥40 220	145	48.0
< 40 235 157 52.0	< 40 235	157	52.0
High density lipoprotein (mg/dl), female: mean (S.D.)=47.1 (12.1)	High density lipoprotein (mg/dl), female: mean (S.D.)=	47.1 (12.1)	
≥50 123 39.9	≥50	123	39.9
< 50 186 60.1	< 50	186	60.1
Duration of DM (year), mean (S.D.)=9.03 (7.04)	Duration of DM (year), mean (S.D.)=9.03 (7.04)		
< 7 301 49.3	< 7	301	49.3
≤7 310 50.7	≤7	310	50.7

Self-care management behaviors

About four fifth (81.3%) of patients did not follow diabetic meal plan as recommended by the dietitians. Two thirds (67.9%) of patients did not participate in physical exercise. Only less than third (38.0%) of patients used to test their blood sugar at home. Most of the patients (92.0%) were highly adherent to their medications.

Variable	Total (%)	No.	%	Р
Gender				.201
Male	302 (49.4)	191	63.3	
Female	309 (50.6)	207	66.9	
Employee				.102
Yes	152 (24.9)	78	51.3	
No	459 (75.1)	320	69.7	
Age (year)				.734
24 -44	115 (18.8)	72	62.6	
45-64	208 (34.0)	138	66.3	
≥65	288 (47.2)	188	65.3	
Level of education				.0005
Illiterate	276 (54.5)	208	75.4	
≤High school	211 (34.5)	150	71.1	
>High school	124 (11)	40	32.3	
Body mass index (kg/m ²)				.003
Normal	202 (33.1)	114	56.4	
Overweight	324 (53.1)	194	59.6	
Obesity	135 (22.1)	103	76.3	
Duration of diabetes (year)				.0005
≤7	311(50.9)	155	50.1	
> 7	300 (49.1)	243	81.0	
Type of diabetic treatment				.0005
* OAA alone	381 (62.4)	186	48.8	
Insulin alone	34 (5.6)	30	88.2	
Combination of OAA and insulin	196 (32.0)	182	92.9	
Hypertension				.401
Yes	404 (66.1)	266	65.8	
No	207 (33.9)	132	63.8	
Cholesterol(mg/dl)				.004
≥ 200	91 (14.9)	69	75.8	
< 200	520 (85.1)	329	63.3	
Triglyceride(mg/dl)				.017
≥150	258 (42.2)	180	69.8	
<150	353 (57.8)	218	61.8	
Low density lipoprotein (mg/dl)				.001

≥100	289 (47.3)	204	70.6	
<100	322 (52.7)	194	60.2	
High density lipoprotein (mg/dl), male				.497
≥ 40	147 (48.7)	90	61.3	
< 40	155 (51.3)	100	64.5	
High-density lipoprotein (mg/dl), fema	ıle			.105
≥ 50	123 (39.8)	77	62.6	
< 50	186 (60.2)	131	70.4	
HbA1c				.102
≥7 %	407 (66.6)	294	72.2	
< 7 %	204 (33.4)	104	51.0	

Glycemic control

Of the total 611 patients, two third (66.6%) had HbA1c \geq 6.5%. Table 2 shows the proportion of patients with poor glycemic control according to demographic, anthropometric, and clinical characteristics. Diabetes was more likely to be poorly controlled among those with increased duration of diabetes, lower level of education, higher BMI, hypercholesterolemia, hypertriglyceridemia, and elevated LDL. The highest level of poor glycemic control was among patients on combination of oral antidiabetic agent and insulin (92.9%). Table 3 shows the proportion of patients with poor glycemic control according to diabetes self-care management behaviors. Poor glycemic control was more common among patients who did not follow dietary regimens by (72.2%), did not practice any physical activity by (70.1%), who did not regularly perform home glucose monitoring by (73.6%) and who were not adherent for medications by (81.6%).

Variable	Total (%)	No.	%	Р
Follow the eating plan as recommended b	1	.0005		
Yes	114 (18.7)	39	34.5	
No	497 (81.3)	359	72.2	
Participate in at least 30 minutes of physi	1	.0005		
Yes	196 (32.1)	107	54.6	
No	415 (67.9)	291	70.1	
Self-monitoring blood glucose		.0005		
Yes	232 (38.0)	119	51.3	
No	379 (62.0)	279	73.6	
Medication adherence		.001		
Highly adherent	562 (92.0)	358	63.7	
Not adherent	49 (8.0)	40	81.6	

Discussion:

This study estimated the proportion of patients with Type 2 diabetes who did not achieve target level of HbA1c in Al-Thawra Hospital in Sana'a. Poor glycemic control (HbA1c 6.5%) was present. Population had HbA1c $\geq 7\%$ (Al-Sultan & Al-Zanki, 2005).

In this study, we found that women suffer from type 2 diabetes more often than men by a ratio of 1:1.02. We also found that the ages ranged from 24 to 84, these results are agreement a study with (Akbar, 2001), and disagree with (Fox, 2006) t was found that men are more susceptible to diabetes than women, as their results were 53% for men.

Finding is consistent with that reported by other studies(Benoit, Fleming, Tsimikas, & Ming, 2005; Valle, Koivisto, Reunanen, Kangas, & Rissanen, 1999; Verma, Paneri, Badi, & Raman, 2006). Longer duration of diabetes is known to be associated with poor control, possibly because of progres- sive impairment of insulin secretion with time because of B- cell failure, which makes the response to diet alone or oral agents unlikely (UK Prospective Diabetes Study (UKPDS) Group, 1998).

In the present study, patients with poor glycemic control were more likely to be prescribed combination of oral antidiabetic agents and insulin, which may indicate that physicians are attempting multitherapy to provide better disease control. The association between treatment with combination of oral antidiabetic agents and insulin and poor glycemic control is consistent with other studies (AL- Nuaim et al., 1998; Goudswarrd, Stolk, Zuithoff, & Rutten, 2004; Valle et al., 1999). This finding reflects the fact of deteriorations of diabetes over time, and the need for higherdoses or additional mediations increases over time. There- fore, patients who were treated by combination therapy of oral antidiabetic agents and insulin had more progressive disease which required more aggressive treatment to provide glycemic control, but this phenomenon could be attributed to delay in applying insulin in the treatment of patients with poor glycemic control.

The lack of a relationship between age and poor glycemic control in our study is not consistent with the findings of a number of studies (EL-Kebbi et al., 2003; Nichols, Hillier, Javor, & Brown, 2000; Rothenbacher, Ruter, Saam, & Brenner, 2003) which reported that younger age was associated with poor glycemic control.

We found that poor glycemic control was more common among patients who were not adherent for medications. Therefore, patients should be motivated to use the medications as prescribed. Despite the importance ofdiet and exercise in control of diabetes, only a small percentage of patients with Type 2 diabetes were adherent to diet regimen and physical activity. Continuous education is recommended to encourage physical activity and diet regimen adherence.

This study was the first study conducted in Makkah to determine the factors associated with poor glycemic control. However, this study is cross sectional, where causal relationship between the independent and dependent variables cannot be established, so a longitudinal study is needed to assess the relationship between those variables over time. At the same time, medication adherence, nutritional intake, testing blood glucose and physical activity were obtained by self-report and may be limited by recall bias.

In conclusion, the proportion of patients with poor glycemic control was high, which is nearly comparable to that reported from many countries. Longer duration of diabetes, and not adherent to diabetes self-care management behaviors were associated with poor glycemic control. An educational program that emphasizes lifestyle modification with importance of adherence to treatment regimen would be of great benefit in poor glycemic control.

Conclusion

The proportion of patients with poor glycemic control was high, which was comparable to that reported from many previous studies. Longer duration of diabetes and not adherent to diabetes self-care management behaviors were associated with poor glycemic control.

Recommendation

Conducting an educational program for diabetic's patients on the importance of adhering to nutrition plan, using medication, and exercise

References:

- Ajlouni, K., Khader, Y., Batieha, A., Ajlouni, H., & EL-khateeb, M. (2008). An increase in prevalence of diabetes mellitus in Jordan during ten years. Journal of Diabetes and its Complications, 22(5), 317–324.
- Akbar, D. H. (2001, July-September). Low rates of diabetic patients reaching good control targets. Eastern Mediterranean Health Journal, 7(4-5), 671–678.
- Al-Nozha, M. M., Al-Maatouq, M. A., Al-Mazrou, Y. Y., et al. (2004). Diabetes mellitus in Saudi Arabia. Saudi Medical Journal, 25(11), 1603–1610.
- AL-Nuaim, A. R., Mirdad, S., AL-Rubeaan, K., et al. (1998). Pattern and factors associated with glycemic control of Saudi diabetic patients. An- nals of Saudi Medicine, 18(2), 109–112.
- Al-Sultan, F. A., & Al-Zanki, N. (2005). Clinical epidemiology of Type 2 diabetes mellitus in Kuwait. Kuwait Medical Journal, 37(2), 98–104.
- American Diabetes Association. (2013). Implications of the United King- dom Prospective Diabetes Study. Diabetes Care, 26, 28–32.
- American Diabetes Association. (2020). Dyslipidemia management in adult with diabetes. Diabetes Care, 24, 68–71.
- American Diabetes Association. (2013). Standards of Medical Care in Diabetes-2013 (position statement). Diabetes Care, 30, S4–S41.
- Benoit, S. R., Fleming, R., Tsimikas, A. P., & Ming, J. I. (2005). Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study. BMC Public Health, 5, 36–45.
- Choo, P. W., Rand, C. S., Inui, T. S., Lee, M. I., & Platt, R. (1999). Validation of patient report, automated pharmacy records, and pill count with electronic monitoring of adherence to anti hypertensive therapy. Medical Care, 37(9), 846–857.
- EL-Kebbi, I. M., Cook, C. B., Ziemer, D. C., et al. (2003). Association of younger age with poor glycemic control and obesity in Urban African Americans with Type 2 diabetes. Archives of Internal Medicine, 163, 69–75. Ezenwaka, C. E., & Offiah, N. V. (2001). Differences in glycemic control and cardiovascular risk in primary care patients with type 2 diabetes in West Indies. Clinical and Experimental Medicine, 2, 91–98.
- Fitzgerald, T., Davis, K., Connell, M., et al. (1996). Development and validation of the diabetes care profile. Evaluation & the Health Professions, 19, 208–230.
- Fox, K. M., Gerber, R. A., Bolinder, B., Chen, J., & Kumar, S. (2006). Prevalence of inadequate glycemic control among patients with Type 2 diabetes in the United Kingdom general practice research data base: A series of retrospective analysis of data from 1998 through 2002. Clinical Therapeutics, 28(3),388–395.
- Glasgow, E., Maccaul, D., & Schafer, C. (1986). Barriers to regimen adherence among person with insulin-dependent diabetes. Journal of Behavioral Medicine, 9(1), 65–77.
- Goudswarrd, A. N., Stolk, R. P., Zuithoff, P., & Rutten, G. (2004). Patients characteristics do not predict poor glycaemic control in Type 2 diabetes patients treated in primary care. European Journal of Epidemiology, 19, 541–545.
- Habib, S. S., & Aslam, M. (2003). Risk factors, knowledge and health status in diabetic patients. Saudi Medical Journal, 24(11), 1219–1224.
- International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 10th edition, 2021, https://diabetesatlas.org/idfawp/resourcefiles/2021/07/IDF_Atlas_10th_Edition_2021.pdf
- Karter, A. J., Moffet, H. H., Liu, J., et al. (2005). Achieving good glycemic control: Initiation of new anti hyperglycemic therapies in patient with Type 2 diabetes from the Kaiser Permanente Northern California diabetes registry. American Journal of Managed Care, 11, 262–270.

- Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004). Glycemic control from 1988 to 2000 among US adults diagnosed with type2 diabetes: A preliminary report. Diabetes Care, 27(1), 17–20.
- Muhammad Farman and Khansa Ghaffar. (2019), Diet and Exercise Effect on Diabetes Mellitus for Healthy Life, JOJ Pub Health 5(3): JOJPH.MS.ID.555665 (2019); PP:
- Rhee, M. K., Slocum, W., Ziemer, D. C., et al. (2005). Patient adherence improves glycemic control. Diabetes Educator, 31, 240–250.
- Rothenbacher, D., Ruter, G., Saam, S., & Brenner, H. (2003). Younger patients with Type 2 diabetes need better glycemic control: Results of a community-based study describing factors associated with a high HbA1c value. British Journal of General Practice, 53, 389–391.
- Saadine, J. B., Engelgau, M. M., Beckles, G. L., et al. (2002). A diabetes report card for the United States: Quality of care in the 1990's. Annals ofInternal Medicine, 136, 565–574.
- Stratton, I. M., Adler, A. I., Neil, H. A. W., et al. (2000). Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321, 405–412.
- The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus. (2012). The AACE system of intensive diabetes self-management—2012 update. Endocrine Practice,8, 40–82.
- The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 101:104. DOI:10.19080JOJPH.2019.05.555665
- Nichols, G. A., Hillier, T. A., Javor, K., & Brown, J. B. (2000). Predictors of glycemic control in insulin using adult with Type 2 diabetes. Diabetes Care, 23(3), 273–277.
- UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood- glucose control with sulphanylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet, 352, 837–853.
- Valle, T., Koivisto, A., Reunanen, A., Kangas, T., & Rissanen, A. (1999). Glycemic control in patients with diabetes in Finland. Diabetes Care, 22 (4), 575–579.
- Verma, M., Paneri, S., Badi, P., & Raman, G. (2006). Effect of increasing duration of diabetes mellitus Type 2 on glycated hemoglobin and insulin sensitivity. Indian Journal of Clinical Biochemistry, 21(1), 142–146.
- Wallace, T. M., & Matthews, D. R. (2020). Poor glycemic control in Type 2 diabetes, conspiracy of disease, suboptimal therapy and attitude. Quar-terly Journal of Medicine, 93, 369–374.
- World Health Organization. (1995). Physical status: The use and interpretation of anthropometry: Report of a WHO Expert committee. Technical report series 854. Geneva.
- Shouip Hossam A. (2014). Diabetes mellitus, Sinai University Journal. https://www.researchgate.net/publication/27 0283336_Diabetes_mellitus